Renalytix PLC (LSE:RENX) - Share price


Stock Report

Renalytix PLC RENX

Last Price
GBX685.00

Day Change
-5.00|-0.72%

As of 29/11/2021
17:48:15 GMT | GBX
Minimum 15 Minutes Delay.

Last Close690.00p
Day Range675.00 - 700.00
Mkt Cap495.30Mil
52-Wk Range450.00 - 1,220.00
Yield %-
ISINGB00BYWL4Y04
Volume37,608
P/E-
P/S326.19
P/CF-19.86

Share Price

Total Returns 29/11/2021

 Chg (%)  
More ...
Renalytix PLC-21.98 
FTSE 100 TR GBP-1.47
 
Financials
201920202021
More ...
Income Statement
Turnover0.000.001.49
Operating Profit-42.34-11.08-32.61
Net Profit-42.30-9.25-31.01
Reported EPS-0.99-0.16-0.43
Balance Sheet
Current Assets9.4217.1976.01
Non Current Assets0.2822.4026.57
Total Assets9.7041.30102.58
Current Liabilities1.153.387.26
Total Liabilities1.155.347.48
Total Equity8.5535.9695.10
Cash Flow
Operating Cash Flow-6.16-10.06-24.63
Net Change in Cash8.935.9451.87
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
31/08/2021SaleMr. O. James Sterling14.446,00086,665.00
09/07/2021Sale of OptionDr. Chirag Rohit Parikh, M.D.,PhD1,000.0015,000150,000.00
09/07/2021Exercise of OptionDr. Chirag Rohit Parikh, M.D.,PhD121.0015,00018,150.00
25/06/2021SaleMr. Christopher Harwood Bernard Mills1,125.006,10068,625.00

Company Profile

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The company's lead product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Sector

Diagnostics & Research

Index

FTSE AIM 100 , FTSE AIM All-Share

Next Event 02/12/2021

First Quarter Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-37.54
Op Mrgn-21.87
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Independent DirectorMr. Christopher Harwood Bernard Mills
Director and Chief Executive OfficerMr. James Renwick McCullough
Director and Chief Technical OfficerMr. Fergus Fleming
Chief Financial Officer and Principal Accounting OfficerMr. O. James Sterling
Independent DirectorDr. Chirag Rohit Parikh, M.D.,PhD
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.